Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy

• Published in: Pharmacogenomics Vol. 13; no. 4; pp. 419 - 427
• Main Authors: Yan, Li, Shu-Ying, Yang, Shan, Kang, Yip, Benjamin H K, Rong-Miao, Zhou, Na, Wang, Hai-Yan, Sun
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.03.2012
• Subjects: Adult; Analysis; Biomarkers, Pharmacological; Cancer; Cancer patients; Carcinoma, Ovarian Epithelial; Care and treatment; Chemotherapy; China; Data processing; Development and progression; DNA-Binding Proteins - genetics; Endonucleases - genetics; ERCC1 protein; Female; Gene polymorphism; Genetic aspects; Genotype; Humans; Medical research; Medicine, Experimental; Middle Aged; Multivariate analysis; Neoplasms, Glandular and Epithelial - drug therapy; Neoplasms, Glandular and Epithelial - genetics; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Patient outcomes; Platinum - therapeutic use; Polymerase chain reaction; Polymorphism, Genetic; Prognosis; Restriction fragment length polymorphism; Risk assessment; Survival; Survival Analysis; China
• ISSN: 1462-2416; 1744-8042
• DOI: 10.2217/pgs.11.181

We evaluated whether the ERCC1 polymorphisms had an effect on survival in epithelial ovarian cancer (EOC) patients with platinum-based chemotherapy. Clinical data of 209 EOC patients between 2002 and 2008 were reviewed. The genotypes of 19007T/C and 8092C/A polymorphisms were assessed in all patients using PCR-RFLP. The 19007T/C polymorphism was significantly associated with response to treatment. Compared with the patients carrying C/C genotype, the patients with the T/T genotype have a significantly decreased response to platinum-based chemotherapy (odds ratio: 32.26; 95% CI: 3.66-250.00). Cox's multivariate analysis suggested that EOC patients with the T/T genotype had an increased risk of disease progression (hazard ratio: 3.34; 95% CI: 1.77-6.29) and death (hazard ratio: 2.87; 95% CI: 1.38-5.96) compared with those carrying the C/C genotype. The 19007T/C polymorphism may be a useful prognostic marker in patients with EOC treated with platinum-based chemotherapy in Chinese women.